Skip to search boxSkip to navigationSkip to main content

Transformation of human CD34+ hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model

  • H. Qin
    ,
  • S. Malek
    ,
  • ,
  • M. Ren(corresponding author)
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease comprising a large number of subtypes defined by specific chromosome abnormalities. One such subtype carries the t(6;9)(p22;q34) chromosome rearrangement, which leads to expression of the DEK-NUP214 chimeric gene, and has a particularly poor outcome. To provide a better understanding of the molecular etiology of these relatively rare individual AML variants, it is necessary to generate in vivo models, which can also serve as a means to evaluate targeted therapies based on their specific genetic abnormalities. Here, we describe the development of a human cell AML, generated in CD34+ human hematopoietic progenitor cells xenografted into immunocompromised mice that express human myeloid cell growth factors. Within 6 months, these mice develop a human cell AML with phenotypic characteristics of the primary t(6;9) disease and a CD45+CD13+CD34+CD38+ immunophenotype. Gene expression studies show that members of the HOX family of genes (HOXA9, 10, B3, B4 and PBX3) are highly upregulated in the AML from this mouse model as well as from primary human t(6;9) AML. Gene expression analysis also identified several other significantly disregulated pathways involving KRAS, BRCA1 and ALK, for example. This is the first report of a humanized model of the DEK-NUP214 disease and provides a means to study the development and treatment of this particular subtype of AML.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 5686-5691 (6 pages)

Journal (Volume, Issue Number)

Oncogene (Volume 35, Issue 43)

Publication milestones

  • Accepted/In press - 04/11/2016
  • Published - 10/27/2016

Publication status

Published - 10/27/2016

ISSN

0950-9232

Publication IDs

  • Scopus: 84963591442
  • PubMed: 27065320

Publication metrics

Metrics

SciVal
FWCI
0.76
SciVal
Author count
4
SciVal
citations
17
SciVal
Paper percentile
83
Fractional count
2
Fractional count
0.50
Fractional count
2
Fractional count
0.50
Fractional count
2
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Captures
31
Citation count
32

Funding Details

FunderFunding number
NCI
R01CA076167